^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CTAG1B expression

    i
    Entrez ID:
    1485
    Related biomarkers:
    Expression
    Others
    Apply
    Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) (NCT03967223)
    Phase 2
    Adaptimmune
    Active, not recruiting
    Last update posted :
    04/25/2024
    Initiation :
    12/31/2019
    Primary completion :
    08/28/2024
    Completion :
    07/31/2026
    HLA-A • CTAG1B
    |
    HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous
    NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors (NCT05881525)
    Phase 1
    TCRCure Biopharma Ltd.
    Recruiting
    Last update posted :
    04/12/2024
    Initiation :
    06/01/2023
    Primary completion :
    10/01/2024
    Completion :
    03/01/2025
    CTAG1B
    |
    CTAG1B expression
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • N201
    Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03206047)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/03/2024
    Initiation :
    11/08/2017
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    PD-L1 • CTAG1B
    |
    PD-L1 expression • CTAG1B expression
    |
    Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)
    Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCI-2018-01758) (NCT03691376)
    Phase 1
    Roswell Park Cancer Institute
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    03/08/2019
    Primary completion :
    01/30/2021
    Completion :
    01/24/2027
    CTAG1B
    |
    CTAG1B expression
    |
    melphalan • Proleukin (aldesleukin)
    Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (NCT02869217)
    Phase 1
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    12/08/2023
    Initiation :
    09/01/2016
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    HLA-A • CTAG1B
    |
    HLA-A*02 • CTAG1B expression
    |
    cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301)
    Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma (NCT03250325)
    Phase 1/2
    Takara Bio Inc.
    Completed
    Last update posted :
    12/06/2023
    Initiation :
    09/20/2017
    Primary completion :
    01/23/2020
    Completion :
    03/09/2022
    HLA-A • CTAG1B
    |
    HLA-A*02 • CTAG1B expression
    |
    cyclophosphamide • mipetresgene autoleucel (TBI-1301)
    Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (NCT04939701)
    Phase 1/2
    Astellas Pharma Global Development, Inc.
    Completed
    Last update posted :
    11/08/2023
    Initiation :
    01/11/2022
    Primary completion :
    06/01/2023
    Completion :
    06/01/2023
    PD-L1 • CTAG1B • SSX1
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • ASP0739
    Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma (NCT03063632)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/25/2023
    Initiation :
    12/14/2017
    Primary completion :
    04/08/2021
    Completion :
    03/14/2023
    IFNG • CTAG1B
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b) • Pembroria (pembrolizumab biosimilar)
    Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (NCT05993299)
    Phase 2
    GlaxoSmithKline
    Active, not recruiting
    Last update posted :
    10/16/2023
    Initiation :
    12/31/2019
    Primary completion :
    10/12/2022
    Completion :
    07/01/2024
    HLA-A • CTAG1B
    |
    HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma (ADP-0011-007) (NCT02992743)
    Phase 2
    GlaxoSmithKline
    Completed
    Last update posted :
    04/11/2023
    Initiation :
    12/06/2016
    Primary completion :
    11/01/2021
    Completion :
    03/22/2022
    HLA-A • CTAG1B
    |
    HLA-A*02 • CTAG1B expression
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer (NCT02737787)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    04/07/2023
    Initiation :
    04/01/2016
    Primary completion :
    04/06/2023
    Completion :
    04/06/2023
    WT1 • MUC16 • CTAG1B
    |
    WT1 expression • CTAG1B expression • WT1 positive
    |
    Opdivo (nivolumab) • Zeltherva (galinpepimut-S)
    NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors (NCT00299728)
    Phase 1
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/10/2022
    Initiation :
    03/21/2006
    Primary completion :
    10/10/2006
    Completion :
    01/10/2014
    CTAG1B • CD4 • CTAG2
    |
    CTAG1B expression • CTAG2 expression
    |
    Promune (agatolimod)
    NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine (NCT00199849)
    Phase 1
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/10/2022
    Initiation :
    09/27/2004
    Primary completion :
    09/11/2006
    Completion :
    09/01/2007
    CD8 • CTAG1B • CD4 • CTAG2
    |
    CTAG1B expression
    Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors (NCT04878484)
    Phase 1
    Athenex, Inc.
    Withdrawn
    Last update posted :
    09/02/2022
    Initiation :
    08/11/2021
    Primary completion :
    10/01/2022
    Completion :
    12/01/2024
    CD8 • CTAG1B
    |
    HLA-A*02:01 • CTAG1B expression
    |
    TCRT-ESO-A2
    A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma (NCT02129075)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    11/16/2021
    Initiation :
    04/09/2014
    Primary completion :
    03/28/2016
    Completion :
    05/18/2018
    CTAG1B • CD4 • PRAME
    |
    CTAG1B expression
    |
    Hiltonol (poly-ICLC) • Mobista (CDX-301) • Neo Vax (NEO-PV-01) • rasdegafusp alfa (CDX-1401)
    A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma (ADP 04511) (NCT01343043)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    06/30/2021
    Initiation :
    09/27/2012
    Primary completion :
    06/18/2019
    Completion :
    06/18/2019
    HLA-A • CTAG1B
    |
    HLA-A*02 • CTAG1B expression
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma (NCT01213472)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    10/09/2019
    Initiation :
    01/31/2011
    Primary completion :
    04/17/2018
    Completion :
    04/17/2018
    CTAG1B
    |
    CTAG1B expression
    |
    GSK2241658A
    CT Antigen TCR-redirected T Cells for Ovarian Cancer. (NCT01567891)
    Phase 1/2
    Adaptimmune
    Completed
    Last update posted :
    06/27/2019
    Initiation :
    07/09/2013
    Primary completion :
    06/06/2017
    Completion :
    06/06/2017
    CTAG1B
    |
    CTAG1B expression
    |
    letetresgene autoleucel (GSK3377794)
    Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 (NCT02122861)
    Phase 1
    Immune Design
    Completed
    Last update posted :
    03/06/2019
    Initiation :
    05/30/2014
    Primary completion :
    11/14/2018
    Completion :
    12/15/2018
    CTAG1B
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • ID-LV305
    NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC (NCT03029273)
    Phase 1
    Guangzhou Institute of Respiratory Disease
    Unknown status
    Last update posted :
    01/17/2019
    Initiation :
    03/21/2017
    Primary completion :
    03/01/2019
    Completion :
    03/01/2019
    EGFR • ALK • CTAG1B
    |
    EGFR mutation • ALK rearrangement • CTAG1B expression
    |
    cyclophosphamide • fludarabine IV • TAEST16001
    Investigator Initiated Phase 1 Study of TBI-1301 (NCT02366546)
    Phase 1
    Mie University
    Unknown status
    Last update posted :
    10/24/2018
    Initiation :
    03/01/2015
    Primary completion :
    09/01/2018
    HLA-A • CTAG1B
    |
    HLA-A*02 • CTAG1B expression
    |
    cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301)
    Safety Study of Adjuvant Vaccine to Treat Melanoma Patients (NCT01079741)
    Phase 2
    Nina Bhardwaj
    Completed
    Last update posted :
    02/13/2018
    Initiation :
    09/01/2010
    Primary completion :
    03/11/2013
    Completion :
    03/11/2013
    CD8 • CTAG1B • CD4
    |
    CD8 expression • CTAG1B expression
    |
    Hiltonol (poly-ICLC)
    A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416)
    Phase 1
    Immune Design
    Completed
    Last update posted :
    08/17/2017
    Initiation :
    11/01/2013
    Primary completion :
    12/01/2016
    Completion :
    03/01/2017
    CTAG1B
    |
    CTAG1B expression
    |
    IDC-G305 • glucopyranosyl lipid A (G100)
    CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors (NCT00819806)
    Phase 1
    Hassane M. Zarour, MD
    Completed
    Last update posted :
    07/31/2017
    Initiation :
    01/01/2009
    Primary completion :
    05/01/2012
    Completion :
    01/01/2015
    CTAG1B
    |
    CTAG1B expression
    |
    cyclophosphamide • Promune (agatolimod)
    NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy (NCT02319824)
    Phase 1
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    07/05/2017
    Initiation :
    01/01/2015
    Primary completion :
    06/01/2015
    CTAG1B
    |
    CTAG1B expression
    Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer (NCT02495636)
    Phase 2
    Yale University
    Withdrawn
    Last update posted :
    06/22/2017
    Initiation :
    07/01/2015
    Primary completion :
    07/01/2017
    Completion :
    07/01/2017
    ALK • CTAG1B
    |
    EGFR mutation • ALK rearrangement • CTAG1B expression • EGFR rearrangement
    |
    Tecentriq (atezolizumab) • rasdegafusp alfa (CDX-1401)
    A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients (NCT02661100)
    Phase 1/2
    Case Comprehensive Cancer Center
    Withdrawn
    Last update posted :
    12/07/2016
    Initiation :
    01/01/2017
    Primary completion :
    07/01/2018
    Completion :
    07/01/2018
    CTAG1B
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)
    T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies (NCT02457650)
    Phase 1
    Shenzhen Second People's Hospital
    Unknown status
    Last update posted :
    08/03/2016
    Initiation :
    04/01/2015
    Primary completion :
    12/01/2019
    Completion :
    12/01/2019
    CTAG1B
    |
    CTAG1B expression • HLA-A2 positive
    |
    cyclophosphamide • fludarabine IV
    A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 (NCT00948961)
    Phase 1/2
    Celldex Therapeutics
    Completed
    Last update posted :
    06/27/2016
    Initiation :
    09/01/2009
    Primary completion :
    06/01/2012
    Completion :
    02/01/2014
    CTAG1B
    |
    CTAG1B expression
    |
    Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)
    NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (NCT02059850)
    Phase 1
    Fred Hutchinson Cancer Center
    Withdrawn
    Last update posted :
    02/03/2016
    Initiation :
    07/01/2014
    Primary completion :
    01/01/2016
    Completion :
    01/01/2016
    CTAG1B
    |
    CTAG1B expression
    |
    cyclophosphamide